Zura Bio Ltd (ZURA)
3.16
+0.13
(+4.29%)
USD |
NASDAQ |
Apr 17, 16:00
3.16
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 137.76M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -72.45% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 2.322 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. |
| URL | https://www.zurabio.com |
| Investor Relations URL | https://investors.zurabio.com/ |
| HQ State/Province | Nevada |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 28, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. |
| URL | https://www.zurabio.com |
| Investor Relations URL | https://investors.zurabio.com/ |
| HQ State/Province | Nevada |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 28, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |